SEC Filing Summary

Charles Theuer, a director at 4D Molecular Therapeutics, Inc., was granted 50,000 stock options on June 17, 2026. These options, with an exercise price of $9.42, are part of the company's non-employee director compensation program. The options vest over three years, with 1/3 vesting on June 17, 2027, and the remainder vesting monthly until fully vested on June 17, 2029. Full vesting is accelerated upon a Change in Control. The options expire on June 16, 2036. Theuer also holds 50,000 shares of Common Stock underlying these options post-transaction.